Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Analysis of the brain of a patient suffering from Parkinson's disease has shown for the first time that the experimental treatment known as GDNF, produced by Amgen, can reverse the loss of nerve fibers.
Subscribe to our email newsletter
During a recent UK study the experimental drug GDNF was administered to five Parkinson’s patients directly into the brain area suffering damage. Within a couple of months, patients were noticing dramatic improvements in their ability to move; improvements which continued for a further four years of treatment. Even after ceasing medication, the improvement has been maintained.
After the unrelated death of one of the participants, a 62-year-old patient, researchers were able to examine directly the effects of the drug on the brain. As the drug had only been infused into one side of the brain, the effects of the treatment could be assessed by comparing the two sides.
Researchers found that dopamine-containing nerve fibers had sprouted back in the putamen. Professor Seth Love from Bristol University, UK said: “This is the first neuropathological evidence that infusion of GDNF in humans causes sprouting of dopamine fibers, in association with a reduction in the severity of Parkinson’s disease.”
The findings may revitalize interest in GDNF administration as a potential therapy for this degenerative condition, providing renewed hope for patients disappointed by the recent withdrawal of this drug due to concerns about its safety.